Development of feline immunodeficiency virus ORF-A (tat) mutants: In vitro and in vivo characterization

Virology

Volumn 298, Issue 1, 2002, Pages 84-95

  Pistello, M ^a   Moscardini, M ^a   Mazzetti, P ^a   Bonci, F ^a   Zaccaro, L ^a   Isola, P ^a   Freer, G ^a   Specter, S ^a   Matteucci, D ^a   Bendinelli, M ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

FIV; FIV tropism; Genetically attenuated mutants; ORF A; ORF A mutant clones; ORF2

Indexed keywords

MUTANT PROTEIN; PROTEIN; PROTEIN ORF A; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; FIBROBLAST; GENE DELETION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; KIDNEY CELL; LYMPHOBLAST; LYMPHOCYTE; LYMPHOID CELL; MACROPHAGE; MOLECULAR CLONING; MONOCYTE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; STOP CODON; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION; WILD TYPE;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS;

EID: 0036302086     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1006/viro.2002.1442     Document Type: Article

References (64)

1. Unusual polymorphisms in human immunodeficiency virus type 1 associated with nonprogressive infection
2. Live attenuated SIV: A model of a vaccine for AIDS
3. Feline immunodeficiency virus infection of cats as a model to test the effect of certain in vitro selection pressures on the infectivity and virulence of resultant lentivirus variants
4. Construction and in vitro characterization of attenuated feline immunodeficiency virus long terminal repeat mutant viruses
5. Vaccination with fixed infected feline immunodeficiency virus (FIV) infected cells: Protection, breakthrough and specificity of response
6. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression
7. Defective nef alleles in a cohort of hemophiliacs with progressing and nonprogressing HIV-1 infection
8. Quantitation of feline immunodeficiency proviruses in doubly infected cats using competitive PCR and a fluorescence-based RFLP
9. The acidic region and conserved putative protein kinase C phosphorylation site in Nef are important for SIV replication in rhesus macaques
10. DNA vaccination using expression vectors carrying structural genes induces immune response against feline immunodeficiency virus
11. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene
12. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node
13. Differential cell tropism of feline immunodeficiency virus molecular clones in vivo
14. Demonstration that orf2 encodes the feline immunodeficiency virus transactivating (Tat) protein and characterization of a unique gene product with partial rev activity
15. Identification of highly attenuated mutants of simian immunodeficiency virus
16. Feline immunodeficiency virus neurotropism: Evidence that astrocytes and microglia are the primary target cells
17. In vivo monocyte tropism of pathogenic feline immunodeficiency viruses
18. Current evidence and future directions for targeting HIV entry: Therapeutic and prophylactic strategies
19. In vivo lymphocyte tropism of feline immunodeficiency virus
20. Mucosal immunization with experimental feline immunodeficiency virus (FIV) vaccines induces both antibody and T cell responses but does not protect against rectal FIV challenge
21. Protection against homologous but not heterologous challenge induced by inactivated feline immunodeficiency virus vaccines
22. DNA vaccination affords significant protection against feline immunodeficiency virus infection without inducing detectable antiviral antibodies
23. Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus
24. Feline immunodeficiency virus subunit vaccines that induce virus neutralising antibodies but no protection against challenge infection
25. Roles of the auxiliary genes and AP-1 binding site in the long terminal repeat of feline immunodeficiency virus in the early stage of infection in cats
26. The roles of vif and ORF-A genes and AP-1 binding site in in vivo replication of feline immunodeficiency virus
27. Oral immunization of macaques with attenuated vaccine virus induces protection against vaginally transmitted AIDS
28. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: Inverse relationship of degree of protection with level of attenuation
29. Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells
30. Partial protection by vaccination with recombinant feline immunodeficiency virus glycoproteins
31. Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan fluorogenic real-time detection system
32. What can be achieved with an HIV vaccine?
33. DNA vaccines: A review
34. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA
35. A neutralizing antibody-inducing peptide of the V3 domain of feline immunodeficiency virus envelope glycoprotein does not induce protective immunity
36. The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation
37. Vaccination protects against in vivo grown FIV even in the absence of detectable neutralizing antibodies
38. AIDS vaccination studies using feline immunodeficiency virus as a model: Immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus
39. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: Detailed analysis of the humoral immune response to a protective vaccine
40. Biological considerations in the development of a human immunodeficiency virus vaccine
41. Simian immunodeficiency virus-specific cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine
42. Thymic lesions in cats infected with a pathogenic molecular clone or an ORF-A/2-deficient molecular clone of feline immunodeficiency virus
43. Identification of the Rev transactivation and Rev-responsive elements of feline immunodeficiency virus
44. Kinetics of preinfecting and challenge virus replication during a three-year interclade feline immunodeficiency virus superinfection experiment in cats
45. Development of tat-deleted mutants of FIV and characterisation of their biological, pathogenic, and immunogenic properties
46. TT virus levels in the plasma of infected individuals with different hepatic and extrahepatic pathologies
47. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates
48. Characterization of three nef-defective human immunodeficiency virus type 1 strains associated with long-term nonprogression
49. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope
50. Delayed infection after immunization with a peptide from the transmembrane glycoprotein of feline immunodeficiency virus
51. Analysis of the vif gene of feline immunodeficiency virus
52. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines
53. Infection of cats with molecularly cloned and biological isolate of the feline immunodeficiency virus
54. Nucleotide sequence and genomic organization of feline immunodeficiency virus
55. The feline immunodeficiency virus ORF-A gene facilitates efficient viral replication in established T-cell lines and peripheral blood lymphocytes
56. Temporal patterns of feline immunodeficiency virus transcripts in peripheral blood cells during the latent stage of infection
57. Molecular biology of the feline immunodeficiency virus auxiliary genes
58. Envelope gene sequences encoding variable regions 3 and 4 are involved in macrophage tropism of feline immunodeficiency virus
59. Influence of ORF2 on host cell tropism of feline immunodeficiency virus
60. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence
61. Immunopathologic changes in the thymus during the acute stage of experimentally induced feline immunodeficiency virus infection in juvenile cats
62. Protection by live, attenuated simian immunodeficiency virus against heterologous challenge
63. Development of IL-2 independent feline lymphoid cell lines chronically infected with feline immunodeficiency virus: Importance for diagnostic reagents and vaccines
64. Experimental vaccine protection against homologous and heterologous strains of feline immunodeficiency virus